CN107183707A - A kind of composition that there is reduction blood glucose to act on and its preparation method and purposes - Google Patents
A kind of composition that there is reduction blood glucose to act on and its preparation method and purposes Download PDFInfo
- Publication number
- CN107183707A CN107183707A CN201710249983.6A CN201710249983A CN107183707A CN 107183707 A CN107183707 A CN 107183707A CN 201710249983 A CN201710249983 A CN 201710249983A CN 107183707 A CN107183707 A CN 107183707A
- Authority
- CN
- China
- Prior art keywords
- composition
- blood glucose
- act
- reduction blood
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008103 glucose Substances 0.000 title claims abstract description 57
- 210000004369 blood Anatomy 0.000 title claims abstract description 47
- 239000008280 blood Substances 0.000 title claims abstract description 47
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000009467 reduction Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 30
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 19
- 241000222336 Ganoderma Species 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 235000020985 whole grains Nutrition 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 235000013402 health food Nutrition 0.000 claims abstract description 4
- 238000005550 wet granulation Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 241000522190 Desmodium Species 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 14
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 7
- 206010013786 Dry skin Diseases 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000013103 analytical ultracentrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of composition that there is reduction blood glucose to act on and preparation method thereof, solve OHA in the prior art and be applied to the problem of specific diabetes type, erious adverse reaction.Said composition is made up of the raw material of following parts by weight：10-30 parts of Herba Lysimachiae extract, 5-10 parts of ganoderma lucidum.Preparation method includes following steps：Weigh raw material；Ganoderma lucidum is crushed, sieves, obtains glossy ganoderma powder；Herba Lysimachiae extract and glossy ganoderma powder are mixed, wet granulation is dried, whole grain, is loaded capsule, is produced.The invention also discloses purposes of the said composition in food, health food and the medicine for preparing reduction blood glucose.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to it is a kind of have reduction blood glucose effect composition and its preparation method and
Purposes.
Background technology
Diabetes are one group of metabolic diseases being characterized with hyperglycaemia.Hyperglycaemia be due to then defect of insulin secretion or
Its biological agent is damaged, or both have concurrently and cause.Long-standing hyperglycaemia during diabetes, cause various tissues, particularly eye,
Kidney, heart, blood vessel, the chronic lesion of nerve, dysfunction.
The cause of disease of diabetes is complicated.It is generally acknowledged that mainly being caused by inherent cause and environmental factor.1 type or diabetes B
There is obvious genetic heterogeneity, 1/4~1/2 patient has Diabetes family history.Clinically at least more than 60 kinds of heredity
Syndrome can be with diabetes.Type 1 diabetes have multiple DNA sites to participate in morbidity, wherein many with DQ sites in HLA antigen genes
State property relation is the closest.A variety of clear and definite gene mutations, such as insulin gene, insulin receptor are had found in diabetes B
Gene, glucokinase gene, chondriogen etc..And feed excessively, obesity is diabetes B caused by physical exertion is reduced
Topmost environmental factor, makes the easily morbidity of the individual with diabetes B genetic predisposition.Type 1 diabetes patient, which exists, to exempt from
Epidemic disease system exception, in some viruses such as Coxsackie virus, rubella virus causes autoimmune response after the infection such as parotid gland virus,
Destroy insulin β cells.
Medicine sulfonylurea drugs, biguanides, α glucosidase inhibitors, the insulin of diabetes are treated at present
Sensitizer and trypsin class medicine.Trypsin class medicine can not be oral, can only inject, inconvenient for use, and patient suffering.Remaining
There is adverse reaction in OHA, there is certain risk when patient uses, and have specific glycosuria to varying degrees
Sick application type.
Therefore a kind of medicine of reduction blood glucose is provided, determined curative effect, adverse reaction is small, using safety, becomes this area
Technical staff's urgent problem to be solved.
The content of the invention
The technical problem to be solved in the present invention is：A kind of composition that there is reduction blood glucose to act on is provided, existing skill is solved
OHA is applied to the problem of specific diabetes type, erious adverse reaction in art.
Present invention also offers a kind of preparation method for the composition that there is reduction blood glucose to act on.
The 3rd mesh of the present invention is the provision of composition in food, health food and the medicine for preparing reduction blood glucose
Purposes.
To achieve the above object, the technical solution adopted by the present invention is as follows：
It is of the present invention it is a kind of have reduction blood glucose effect composition, said composition by following parts by weight raw material system
Into：10-30 parts of Herba Lysimachiae extract, 5-10 parts of ganoderma lucidum.
Preferably, the composition is made up of the raw material of following parts by weight：14-25 parts of Herba Lysimachiae extract, ganoderma lucidum 6-9
Part.
Preferably, the composition is made up of the raw material of following parts by weight：20 parts of Herba Lysimachiae extract, 8 parts of ganoderma lucidum.
Preferably, the Herba Lysimachiae extract is that desmodium is made after high concentration ethanol extraction with aqueous solution.
Preferably, the preparation method of the Herba Lysimachiae extract is：Desmodium is taken to add the 70- of its 4-6 times of quality
100% ethanol water, is heated to reflux 2-4 times, each 1-2 hours, filtering, merging filtrate, filtrate recycling ethanol, concentration,
Dry, produce.
Preferably, the composition is the Chinese medicine preparation being prepared into using Herba Lysimachiae extract, ganoderma lucidum as raw material.
Preferably, the Chinese medicine preparation is oral formulations.
Preferably, the oral formulations are tablet, capsule, mixture, granule, soft extract, powder.
The preparation method of composition of the present invention, it is characterised in that：Comprise the following steps：
1) raw material is weighed by weight；
2) ganoderma lucidum is crushed, sieves, obtain glossy ganoderma powder；
3) Herba Lysimachiae extract and glossy ganoderma powder are mixed, wet granulation is dried, whole grain, is loaded capsule, is produced.
Purposes of the composition of the present invention in food, health food and the medicine for preparing reduction blood glucose.
Compared with prior art, the invention has the advantages that：
(1) present invention is matched somebody with somebody from Herba Lysimachiae extract and ganoderma lucidum as bulk drug by scientific composition, by certain weight
Than composition.Both use compatibility, can cooperate with action, play a part of reducing blood glucose jointly.
(2) desmodium and ganoderma lucidum in the present invention have long-term edible history, and security is good, and adverse reaction is small, fits
It is wide with crowd, it is applicable for polytype diabetes.
(3) present invention, using scientific and rational preparation method, ganoderma lucidum is beaten after powder and is used as medicine, most according to the characteristic of bulk drug
Active ingredient is remained to limits, safely and effectively preparation is prepared so that effect is taken more stable, controllable.
(4) present invention employs oral formulations, conveniently produce, store, transport, carry and take.
Embodiment
With reference to specific embodiment, the invention will be further described, and mode of the invention includes but are not limited to following
Embodiment.
Embodiment 1
Prepare Herba Lysimachiae extract.
Desmodium 1000g is taken, 400ml 70% ethanol water is added, is heated to reflux 2 times, 2 hours every time, is filtered, close
And filtrate, filtrate recycling ethanol, concentrate, 80 DEG C of dryings are produced.
Embodiment 2
Prepare Herba Lysimachiae extract.
Desmodium 1000g is taken, 600ml 95% ethanol water is added, is heated to reflux 4 times, 1 hour every time, is filtered, close
And filtrate, filtrate recycling ethanol, concentration, 80 DEG C of vacuum drying, produce.
Embodiment 3
Composition：Herba Lysimachiae extract 100g, ganoderma lucidum 100g.
Preparation method：Weigh Herba Lysimachiae extract 100g, ganoderma lucidum 100g；Ganoderma lucidum is crushed, 100 mesh sieves is crossed, obtains glossy ganoderma powder；
Herba Lysimachiae extract and glossy ganoderma powder are mixed, plus 70% ethanol wet, granulation, in 50 DEG C of dryings, whole grain loads capsule, produced.
Embodiment 4
Composition：Herba Lysimachiae extract 300g, ganoderma lucidum 50g.
Preparation method：Weigh Herba Lysimachiae extract 300g, ganoderma lucidum 50g；Ganoderma lucidum is crushed, 80 mesh sieves is crossed, obtains glossy ganoderma powder；Will
Herba Lysimachiae extract is mixed with glossy ganoderma powder, plus 75% ethanol wet, granulation, and in 70 DEG C of dryings, whole grain loads capsule, produced.
Embodiment 5
Composition：Herba Lysimachiae extract 140g, ganoderma lucidum 90g.
Preparation method：Weigh Herba Lysimachiae extract 140g, ganoderma lucidum 90g；Ganoderma lucidum is crushed, 120 mesh sieves is crossed, obtains glossy ganoderma powder；
Herba Lysimachiae extract and glossy ganoderma powder are mixed, plus 75% ethanol wet, granulation, in 80 DEG C of dryings, whole grain loads capsule, produced.
Embodiment 6
Composition：Herba Lysimachiae extract 250g, ganoderma lucidum 60g.
Preparation method：Weigh Herba Lysimachiae extract 250g, ganoderma lucidum 60g；Ganoderma lucidum is crushed, 80 mesh sieves is crossed, obtains glossy ganoderma powder；Will
Herba Lysimachiae extract is mixed with glossy ganoderma powder, plus 50% ethanol wet, granulation, and in 40 DEG C of dryings, whole grain loads capsule, produced.
Embodiment 7
Composition：Herba Lysimachiae extract 200g, ganoderma lucidum 80g.
Preparation method：Weigh Herba Lysimachiae extract 200g, ganoderma lucidum 80g；Ganoderma lucidum is crushed, 120 mesh sieves is crossed, obtains glossy ganoderma powder；
Herba Lysimachiae extract and glossy ganoderma powder are mixed, plus 90% ethanol wet, granulation, in 60 DEG C of dryings, whole grain loads capsule, produced.
Embodiment 8
Hypoglycemic is tested.
Experiment sample：Sample made from Example 3 is counted as sample, specification 0.3g/, and people's oral recommended dose is
Everyone (adult) 3 times a day, 2 every time, and adult's body weight is calculated by 60kg, and it is 30mg/kgBW to convert into dosage.
Experimental animal：SPF grades of healthy adult SD kind male rats, body weight is l50 ± 20 gram.
Dosage choice gives mode with tested material：Consumption is recommended according to the human body of the sample, if 75mg/kgBW (low dosages
Group), 150mg/kgBW (middle dose group), 300mg/kgBW (high dose group) (be respectively equivalent to human body recommend consumption 2.5,5,
10 times) test group of 3*2 dosage, while set a model group control group and a blank control group, separately set one it is normal dynamic
The test sample group (high dose) and control group of thing, every group of 15 rats.The content for weighing each dose of group of sample respectively adds water, and mixes
It is even, be made into 25,50,100mg/mL strength solutions, corresponding agent gavage is given respectively, the test sample group of intact animal is given
100mg/mL strength solutions, gavage volume is lmg/100gBw, and model control group, blank control group and intact animal control group are given
Give isometric pure water, daily gavage once, continuous gavage 33 days.
Experimental implementation：Healthy male rat, gives common maintenance material and adapts to raise 5 days, fasting 4 hours, and the intraocular corner of the eyes takes blood,
Determine to (i.e. 0 hour) blood glucose value before glucose, it is dynamic as the batch to 0.5,2 hours blood glucose values after 2.5g/kgBW glucose
Thing basic value.With 0,0.5 hours blood glucose 8 groups of level point, i.e., 1 blank control group, 1 model control group and 3*2 dosage
Group, every group 15.Blank control group is not processed, and 3*2 dosage group gavage gives various concentrations given the test agent, model control group
Give same volume pure water, continuous 33 days.Each group is given maintenance material and raised, and model control group and 3 dosage groups change hyperpyrexia after 1 week
Energy feed, after being fed with 3 weeks, model control group and 3 dosage fasting 24 hours (can't help water) give alloxan 104mg/kgBW
Intraperitoneal injection, injection volume lmL/100g body weight.Continue to give high heat energy forage feed 5 days after injection.Off-test, each group animal
Fasting 4 hours, detection fasting blood-glucose, sugar tolerance, serum insulin and cholesterol (TG), triglycerides (TC) level.
Fasting blood-glucose, carbohydrate tolerance test：Each group animal fasting 4 hours, determines fasting blood-glucose i.e. to (0 hour) before glucose
Blood glucose value, dosage group gives various concentrations given the test agent, and model control group gives same volume pure water, and blank control group, which is not done, to be located
Reason, each group oral administration of glucose 2.5g/100gBw after l5 minutes is determined to each group after glucose 0.5, the blood glucose value of 2 hours.
If the hours blood glucose value of model control group 0.5 is more than or equal to 10mmol/L, or model control group 0.5 hour, 2 hours any times
Point blood glucose rise or Area under the curve of blood glucose rise, are compared, difference has conspicuousness, decision model glycometabolism is disorderly with blank control group
Disorderly set up.On the premise of model is set up, given the test agent dosage group is compared with model control group, and fasting blood-glucose difference has statistics
Meaning, that is, judge that the given the test agent fasting blood-glucose index result is positive；Given the test agent dosage group is compared with model control group, to
0.5 after glucose, 2 hours any time point blood glucose decline statistically significant, or 0,0.5,2 hours blood glucose TG-AUCs drop
It is low statistically significant, that is, judge that the given the test agent sugar tolerance index result is positive.
Blood lipids index：Each group animal fasting 4 hours, detection serum cholesterol, triglyceride, if model control group serum courage
Sterol or triglycerides it is significantly raised it is many compared with blank control group, difference has conspicuousness, the establishment of decision model disorders of lipid metabolism.
Many given the test agent dosage groups are compared with model control group on the premise of model is set up, and serum cholesterol or triglycerides decline have
Statistical significance, can determine that the given the test agent reducing blood lipid index is positive.
Intact animal：Healthy adult animal is selected, is grouped by the hours blood glucose level of fasting 4 in being randomly divided into test sample group
(high dose) and blank control group, every group of 15 rats.Sample sets give l00mg/mL concentration samples solution, and gavage volume is
1mL/100gBW, blank control group gives isometric pure water, and once, continuous gavage 33 days, experiment terminates to determine daily gavage
The fasting blood-glucose (fasting 44 hours) of rat.
Result judgement：An index positive in fasting blood-glucose and sugar tolerance binomial index, and blood fat (T-CHOL, glycerine
Three esters) without significantly raised, on intact animal fasting blood-glucose without influence, you can judge the given the test agent function of blood sugar reduction zoopery
As a result it is positive.
The carbohydrate tolerance test result table of each group rat before table 1 is tested
As seen from the above table, area discrepancy is without conspicuousness under blood glucose and blood glucose between each group rat before testing, and each group rat is real
Sugar tolerance is without significant difference before testing.
The carbohydrate tolerance test result of each group rat during 2 off-test of table
Note：## is compared with blank control group, and P ＜ 0.01, * * are compared with model group, P ＜ 0.01.
From after upper table, off-test, after gavage glucose, 0h, 0.5h, 2.5h blood glucose and blood of model control group
Sugared TG-AUC is higher than blank control group, and 0.5h and 2 hours blood glucose values>10mmol/L, has compared with blank control group
Difference (the P of highly significant<0.01), show that hyperglycemia model is set up.After gavage glucose, each dosage group of 0h, 0.5h sample
Blood glucose compared no significant difference (P with model control group>0.05), it is significantly lower than mould in the blood glucose value of each dosage group of 2h samples
Type control group (P<0.01), difference highly significant.Show that this product has good reduction blood glucose effect.
The blood fat of each group rat, insulin content testing result at the end of table 3 is tested
Note：#, ## are compared with blank control group, respectively P<0.05、P<0.0l；*, * * are compared with model control group, respectively P<
0.05、P<0.0l。
From table 3, at the end of experiment, the serum TC of model control group, TG contents are higher than blank control group, and tool difference
Property.
Animal experiment shows that the present invention is acted on good reduction blood glucose.
Embodiment 9
The clinical practice of the present invention.
Patient Jiang, man, 33 years old, type 1 diabetes, fasting blood-glucose was 10.3mmol/L, using the basis of insulin therapy
On, the sample that daily prepared by the embodiment of the present invention 1,3 times a day, 2 every time.Stop insulin, alone hair after January
It is bright.After two months, fasting blood-glucose maintains 8mmol/L or so, takes this product and has no adverse reaction.
Embodiment 10
The clinical practice of the present invention.
Patient's fourth, man, 55 years old, diabetes B, fasting blood-glucose was 9.7mmol/L, daily the embodiment of the present invention 1
The sample of preparation, 3 times a day, 2 every time.Fasting blood-glucose 7.5mmol/L after January, takes this product and has no adverse reaction.
Above-described embodiment is only one of the preferred embodiment of the present invention, should not be taken to limit the protection model of the present invention
Enclose, as long as the present invention body design thought and mentally make have no the change of essential meaning or polishing, it is solved
Technical problem it is still consistent with the present invention, should be included in protection scope of the present invention within.
Claims (10)
1. a kind of composition that there is reduction blood glucose to act on, it is characterised in that：The composition by following parts by weight raw material system
Into：10-30 parts of Herba Lysimachiae extract, 5-10 parts of ganoderma lucidum.
2. a kind of composition that there is reduction blood glucose to act on according to claim 1, it is characterised in that：The composition by
The raw material of following parts by weight is made：14-25 parts of Herba Lysimachiae extract, 6-9 parts of ganoderma lucidum.
3. a kind of composition that there is reduction blood glucose to act on according to claim 2, it is characterised in that：The composition by
The raw material of following parts by weight is made：20 parts of Herba Lysimachiae extract, 8 parts of ganoderma lucidum.
4. a kind of composition that there is reduction blood glucose to act on according to claim 1-3 any one, it is characterised in that：
The Herba Lysimachiae extract is that desmodium is made after high concentration ethanol extraction with aqueous solution.
5. a kind of composition that there is reduction blood glucose to act on according to claim 4, it is characterised in that：The desmodium carries
The preparation method for taking thing is：Take desmodium to add the 70-100% ethanol waters of its 4-6 times of quality, be heated to reflux 2-4
Secondary, each 1-2 hours, filtering, merging filtrate, filtrate recycling ethanol is concentrated, and is dried, is produced.
6. a kind of composition that there is reduction blood glucose to act on according to claim 5, it is characterised in that：The composition is
The Chinese medicine preparation being prepared into using Herba Lysimachiae extract, ganoderma lucidum as raw material.
7. a kind of composition that there is reduction blood glucose to act on according to claim 6, it is characterised in that：The Chinese medicine preparation
For oral formulations.
8. a kind of composition that there is reduction blood glucose to act on according to claim 7, it is characterised in that：The oral formulations
For tablet, capsule, mixture, granule, soft extract, powder.
9. the preparation method of the composition according to claim 1-8 any one, it is characterised in that：Comprise the following steps：
1) raw material is weighed by weight；
2) ganoderma lucidum is crushed, sieves, obtain glossy ganoderma powder；
3) Herba Lysimachiae extract and glossy ganoderma powder are mixed, wet granulation is dried, whole grain, is loaded capsule, is produced.
10. the composition as described in claim 1-9 any one is preparing food, health food and the medicine of reduction blood glucose
In purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710249983.6A CN107183707A (en) | 2017-04-17 | 2017-04-17 | A kind of composition that there is reduction blood glucose to act on and its preparation method and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710249983.6A CN107183707A (en) | 2017-04-17 | 2017-04-17 | A kind of composition that there is reduction blood glucose to act on and its preparation method and purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107183707A true CN107183707A (en) | 2017-09-22 |
Family
ID=59872006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710249983.6A Pending CN107183707A (en) | 2017-04-17 | 2017-04-17 | A kind of composition that there is reduction blood glucose to act on and its preparation method and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107183707A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112216394A (en) * | 2019-07-11 | 2021-01-12 | 浙江远图互联科技股份有限公司 | Blood glucose change trend prediction system based on self-adaptive optimization model |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486742A (en) * | 2003-07-24 | 2004-04-07 | 上海绿谷（集团）有限公司 | Capsule prepn for regulating blood fat and blood sugar |
| CN1660388A (en) * | 2004-12-14 | 2005-08-31 | 南京中科生化技术有限公司 | Oral Chinese material medica preparation for regulating blood sugar and improving immunologic function and preparation method |
| CN1891240A (en) * | 2005-07-01 | 2007-01-10 | 西安绿谷制药有限公司 | Chinese medicine composition containing multi glossy ganoderma active constituents and its preparing method |
| CN105999174A (en) * | 2016-07-06 | 2016-10-12 | 侯添有 | Traditional Chinese medicine for treating diabetes and preparation method thereof |
-
2017
- 2017-04-17 CN CN201710249983.6A patent/CN107183707A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486742A (en) * | 2003-07-24 | 2004-04-07 | 上海绿谷（集团）有限公司 | Capsule prepn for regulating blood fat and blood sugar |
| CN1660388A (en) * | 2004-12-14 | 2005-08-31 | 南京中科生化技术有限公司 | Oral Chinese material medica preparation for regulating blood sugar and improving immunologic function and preparation method |
| CN1891240A (en) * | 2005-07-01 | 2007-01-10 | 西安绿谷制药有限公司 | Chinese medicine composition containing multi glossy ganoderma active constituents and its preparing method |
| CN105999174A (en) * | 2016-07-06 | 2016-10-12 | 侯添有 | Traditional Chinese medicine for treating diabetes and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈艳等: "《糖尿病患者衣食住行》", 31 October 2013, 金盾出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112216394A (en) * | 2019-07-11 | 2021-01-12 | 浙江远图互联科技股份有限公司 | Blood glucose change trend prediction system based on self-adaptive optimization model |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104688822A (en) | Tablet for assisting to reduce blood glucose and preparation method | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN101019645B (en) | Health food for remitting fatigue and raising hypoxia tolerance and its preparation method | |
| CN107343658A (en) | A kind of antifatigue SOD oyster peptides complex capsule and preparation method thereof | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106177434A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Rhizoma Polygonati Odorati | |
| CN107183707A (en) | A kind of composition that there is reduction blood glucose to act on and its preparation method and purposes | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN105055851B (en) | A kind of Chinese medicine composition that treating diabetes, its preparation and its application | |
| CN104127816B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN107441332A (en) | The ginseng composition and preparation method of auxiliary adjustment endocrine metabolism and anti-cancer and cancer-preventing | |
| WO2018072276A1 (en) | Health-care food and preparation method therefor | |
| CN104055115B (en) | A kind of health products containing agate coffee, the stem of noble dendrobium and Panax Japonicus Var. Major and preparation method thereof | |
| CN106722918A (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN104940594A (en) | Application of brain preparation in the preparation of medicine for curing II-type diabetes mellitus and complications thereof | |
| CN101579121A (en) | Nutritional food with hpyerglycemic function and preparation method thereof | |
| CN101537079B (en) | Pharmaceutical composition or health-care product for improving sleeping and delaying senility and preparation method thereof | |
| CN104273527B (en) | A kind of health composition and its production and use | |
| CN111214641A (en) | Traditional Chinese medicine preparation for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170922 |